1US Renal Data System. 1998 Annual Data Report. Bethesda, National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, 1998, 63-90
2Mathur S, Devaraj S, Jialal I. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end- stage renal disease. Curr Opin Nephrol Hypertens, 2002, 11(2): 141 - 147
3Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344(8934): 1383 - 1389
4Prichard SS. Impact of dyslipidemia in end - stage renal disease. J Am Soc Nephrol, 2003, 14(9 Suppl 4): S315 -S320
5Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis, 1993, 21(6): 573 -591
6Avram MM, Goldwasser P, Burrell DE, et al. The uremic dyslipidemia:A cross - sectional and longitudinal study. Am J Kidney Dis, 1992, 20(4): 324 - 335
7Johansson AC, Samuelsson O, Attman PO, et al. Dyslipidemia in peritoneal dialysis - relation to dialytic variables. Perit Dial Int, 2000, 20(3): 306-314
8Bredie SJ, Bosch FH, Demacker PN, etal. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int, 2001, 21(3): 275-281
9Kagan A, Bar- Khayim Y, Schafcr Z, et al. Kinetics of peritoneal protein loss during CAPD. Ⅱ. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int, 1990, 37(3): 980-990
10Seliger SL, Weiss NS, Gillen DL, et al. HMG- CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int, 2002, 61(1): 297-304
